Sumitomo Pharma Am Drug Patent Portfolio
Sumitomo Pharma Am owns 3 orange book drugs protected by 45 US patents Given below is the list of Sumitomo Pharma Am's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10744277 | Aerosol delivery device and method of operating the aerosol delivery device | 07 Dec, 2036 | Active |
| US10688518 | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator | 12 Nov, 2036 | Active |
| US10449146 | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | 19 Apr, 2036 | Active |
| US10959943 | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa | 19 Apr, 2036 | Active |
| US10376661 | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element | 14 Sep, 2035 | Active |
| US9604018 | Aerosol therapy device | 16 May, 2033 | Active |
| US9168556 | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer | 01 Sep, 2032 | Active |
| US9750747 | Treatments involving eslicarbazepine acetate or eslicarbazepine | 24 Aug, 2032 | Active |
| US11419769 | Sublingual films | 16 Dec, 2031 | Active |
| US8414922 | Sublingual films | 16 Dec, 2031 | Active |
| US8846074 | Sublingual films | 16 Dec, 2031 | Active |
| US9789270 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized | 30 Oct, 2030 | Active |
| US10420763 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US9044475 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US9283219 | Sublingual films | 11 Jun, 2030 | Active |
| US9326981 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US9669019 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US9669021 | Sublingual apomorphine | 11 Jun, 2030 | Active |
| US8372431 | Pharmaceutical composition comprising licarbazepine acetate | 17 Apr, 2030 | Active |
| US10821074 | Sublingual and buccal film compositions | 07 Aug, 2029 | Active |
| US10940110 | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations | 26 Feb, 2029 | Active |
| US9265900 | Disposable ampoule for an aerosol generating device | 07 Dec, 2028 | Active |
| US10912781 | Pharmaceutical composition comprising licarbazepine acetate | 23 Oct, 2028 | Active |
| US9566244 | Pharmaceutical composition comprising licarbazepine acetate | 23 Oct, 2028 | Active |
| US9763954 | Therapeutical uses of eslicarbazepine | 13 Sep, 2028 | Active |
| US11278683 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized | 16 Aug, 2026 | Active |
| US9206135 | Asymmetric catalytic reduction of oxcarbazepine | 21 Apr, 2026 | Active |
| US9643929 | Asymmetric catalytic reduction of oxcarbazepine | 21 Apr, 2026 | Active |
| US7931212 | Fluid droplet production apparatus and method | 25 Nov, 2025 | Active |
| US10675287 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | 06 May, 2025 | Active |
| US10695354 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | 06 May, 2025 | Active |
| US10702536 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | 06 May, 2025 | Active |
| US11364247 | Methods of treatment of partial onset seizures using eslicarbazepine acetate | 06 May, 2025 | Active |
| US7458372 | Inhalation therapy device | 18 Nov, 2024 | Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 03 Apr, 2024 | Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 20 Feb, 2024 | Expired |
| US8511581 | Fluid droplet production apparatus and method | 08 Nov, 2023 | Expired |
| US8663687 | Film compositions for delivery of actives | 02 Feb, 2023 | Expired |
| US7316067 | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step | 06 Sep, 2022 | Expired |
| US10888499 | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom | 14 Feb, 2022 | Expired |
| US11077068 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 14 Feb, 2022 | Expired |
| US9855221 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 14 Feb, 2022 | Expired |
| US9931305 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 14 Feb, 2022 | Expired |
| US5753646 | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them | 27 Jun, 2021 | Expired |
| US6962151 | Inhalation nebulizer | 27 Oct, 2020 | Expired |
Latest Legal Activities on Sumitomo Pharma Am's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sumitomo Pharma Am.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Feb, 2024 | US10744277 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Dec, 2023 | US10702536 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Dec, 2023 | US10695354 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Dec, 2023 | US10688518 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Nov, 2023 | US10675287 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Nov, 2023 | US9326981 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2023 | US9283219 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Jun, 2023 | US9206135 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Apr, 2023 | US10449146 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Apr, 2023 | US9168556 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Mar, 2023 | US10420763 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Mar, 2023 | US11419769 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Mar, 2023 | US9283219 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Mar, 2023 | US8414922 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 10 Mar, 2023 | US10449146 |
Sumitomo Pharma Am's Drug Patent Litigations
Sumitomo Pharma Am's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. as the respondent. Click below to track the latest information on how companies are challenging Sumitomo Pharma Am's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | November, 2016 |
Terminated-Settled
(06 Oct, 2017)
| MonoSol Rx, LLC et al. | Mylan Technologies, Inc. et al. |
| US8603514 | May, 2016 |
Terminated-Denied
(05 Dec, 2016)
| MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8603514 | December, 2015 |
Terminated-Denied
(23 May, 2016)
| MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8765167 | October, 2014 |
FWD Entered
(24 Mar, 2016)
| MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Settled
(24 Mar, 2016)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Denied
(20 May, 2015)
| MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
Sumitomo Pharma Am Drug Patents' Oppositions Filed in EPO
Sumitomo Pharma Am drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP14815314A | Feb, 2021 | Vectura Limited | Opposition rejected |
| EP15175258A | May, 2019 | D Young & Co LLP | Granted and Under Opposition |
| EP08842368A | Jun, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Opposition rejected |
| EP08705172A | Jun, 2017 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Revoked |
| EP08705172A | Jun, 2017 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Revoked |
| EP10786915A | May, 2016 | LTS LOHMANN Therapie-Systeme AG | Granted and Under Opposition |
| EP10786915A | May, 2016 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP11157819A | Jun, 2014 | Ahrens, Gabriele | Patent maintained as amended |
| EP02782151A | Jun, 2013 | Acino Pharma AG | Revoked |
| EP02782151A | Jun, 2013 | Germann, Sandra | Revoked |
| EP02801042A | Sep, 2012 | Ahrens, Gabriele | Patent maintained as amended |
| EP02801042A | Sep, 2012 | LTS LOHMANN Therapie-Systeme AG | Patent maintained as amended |
Sumitomo Pharma Am's Family Patents
Sumitomo Pharma Am drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 34.7% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Sumitomo Pharma Am Drug List
Given below is the complete list of Sumitomo Pharma Am's drugs and the patents protecting them.
1. Aptiom
Aptiom is protected by 12 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9750747 | Treatments involving eslicarbazepine acetate or eslicarbazepine |
24 Aug, 2032
(7 years from now)
| Active |
| US8372431 | Pharmaceutical composition comprising licarbazepine acetate |
17 Apr, 2030
(5 years from now)
| Active |
| US10912781 | Pharmaceutical composition comprising licarbazepine acetate |
23 Oct, 2028
(3 years from now)
| Active |
| US9566244 | Pharmaceutical composition comprising licarbazepine acetate |
23 Oct, 2028
(3 years from now)
| Active |
| US9763954 | Therapeutical uses of eslicarbazepine |
13 Sep, 2028
(3 years from now)
| Active |
| US9206135 | Asymmetric catalytic reduction of oxcarbazepine |
21 Apr, 2026
(1 year, 5 months from now)
| Active |
| US9643929 | Asymmetric catalytic reduction of oxcarbazepine |
21 Apr, 2026
(1 year, 5 months from now)
| Active |
| US10675287 | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
06 May, 2025
(5 months from now)
| Active |
| US10695354 | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
06 May, 2025
(5 months from now)
| Active |
| US10702536 | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
06 May, 2025
(5 months from now)
| Active |
| US11364247 | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
06 May, 2025
(5 months from now)
| Active |
| US5753646 | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
27 Jun, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aptiom's drug page
2. Kynmobi
Kynmobi is protected by 19 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10449146 | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
19 Apr, 2036
(11 years from now)
| Active |
| US10959943 | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
19 Apr, 2036
(11 years from now)
| Active |
| US11419769 | Sublingual films |
16 Dec, 2031
(7 years from now)
| Active |
| US8414922 | Sublingual films |
16 Dec, 2031
(7 years from now)
| Active |
| US8846074 | Sublingual films |
16 Dec, 2031
(7 years from now)
| Active |
| US10420763 | Sublingual apomorphine |
11 Jun, 2030
(5 years from now)
| Active |
| US9044475 | Sublingual apomorphine |
11 Jun, 2030
(5 years from now)
| Active |
| US9283219 | Sublingual films |
11 Jun, 2030
(5 years from now)
| Active |
| US9326981 | Sublingual apomorphine |
11 Jun, 2030
(5 years from now)
| Active |
| US9669019 | Sublingual apomorphine |
11 Jun, 2030
(5 years from now)
| Active |
| US9669021 | Sublingual apomorphine |
11 Jun, 2030
(5 years from now)
| Active |
| US10821074 | Sublingual and buccal film compositions |
07 Aug, 2029
(4 years from now)
| Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
03 Apr, 2024
(7 months ago)
| Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
20 Feb, 2024
(8 months ago)
| Expired |
| US8663687 | Film compositions for delivery of actives |
02 Feb, 2023
(1 year, 9 months ago)
| Expired |
| US10888499 | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
14 Feb, 2022
(2 years ago)
| Expired |
| US11077068 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
14 Feb, 2022
(2 years ago)
| Expired |
| US9855221 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
14 Feb, 2022
(2 years ago)
| Expired |
| US9931305 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
14 Feb, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kynmobi's drug page
3. Lonhala Magnair Kit
Lonhala Magnair Kit is protected by 14 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10744277 | Aerosol delivery device and method of operating the aerosol delivery device |
07 Dec, 2036
(12 years from now)
| Active |
| US10688518 | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
12 Nov, 2036
(11 years from now)
| Active |
| US10376661 | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element |
14 Sep, 2035
(10 years from now)
| Active |
| US9604018 | Aerosol therapy device |
16 May, 2033
(8 years from now)
| Active |
| US9168556 | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer |
01 Sep, 2032
(7 years from now)
| Active |
| US9789270 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
30 Oct, 2030
(5 years from now)
| Active |
| US10940110 | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations |
26 Feb, 2029
(4 years from now)
| Active |
| US9265900 | Disposable ampoule for an aerosol generating device |
07 Dec, 2028
(4 years from now)
| Active |
| US11278683 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized |
16 Aug, 2026
(1 year, 8 months from now)
| Active |
| US7931212 | Fluid droplet production apparatus and method |
25 Nov, 2025
(1 year, 9 days from now)
| Active |
| US7458372 | Inhalation therapy device |
18 Nov, 2024
(2 days from now)
| Active |
| US8511581 | Fluid droplet production apparatus and method |
08 Nov, 2023
(1 year, 8 days ago)
| Expired |
| US7316067 | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
06 Sep, 2022
(2 years ago)
| Expired |
| US6962151 | Inhalation nebulizer |
27 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lonhala Magnair Kit's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List